Because SMAD4 mutated or deleted pancreatic cancers have an increased reliance on autophagy for treatment resistance, we hypothesized that patients with SMAD4 tumor loss/mutation would derive the greatest benefit from autophagy inhibition with HCQ. Here, SMAD4 is linked to pancreatic neoplasm.